中证报中证网讯(记者吴科任)8月27日晚，成都先导发布2025年半年度报告。报告期内，公司实现营业 收入2.27亿元，同比增长16.58%；归母净利润5004.20万元，同比增长390.72%；扣非净利润5391.19万 元，同比增长2517.66%；经营活动产生的现金流量净额为1.11亿元，同比增长51.48%。 根据财报，上半年，成都先导积极把握市场机遇，以全球化视野深化合作，通过国内外资源共享与优势 互补，持续优化国际市场策略，进一步提升市场定位的精准性与业务运营效率。公司有序推进各技术平 台的商业项目与研究项目，并积极探索商业化落地，实现业绩同步增长。同时，公司母公司和英国子公 司Vernalis对研发投入进行结构性调整，在保持技术创新能力的同时，显著提升了资源配置效率。 成都先导董事长兼首席执行官李进表示："2025年以来，成都先导继续保持良好的发展势头，营业收 入、利润、毛利率均再次实现增长，整体业绩再上新台阶。公司持续深化外部合作，不断提升内部创新 能力，培育发展新动能，进一步激发了长期稳定发展的动力与韧性。未来，公司将始终坚持以创新驱动 发展，积极推动构建药物研发新范式和新生态，为股东、客户和 ...

半年报显示，报告期内，成都先导各技术平台商业项目与研究项目均按计划有序推进。得益于主营业务 收入稳健增长及毛利率同步提升，本期利润显著增厚。作为成都先导的基石业务，DEL板块实现收入 1.02亿元，同比增长40.45%，增速明显。其次，英国子公司Vernalis 在本期确认里程碑收入，进一步巩 固了FBDD/SBDD 平台的稳步发展。OBT 板块在持续拓展传统核苷单体合成业务的同时，借助递送分 子相关服务，实现了小核酸一站式项目的商业转化。TPD板块在2025年积极探索新业务模式，与合作伙 伴共同启动基于 PROTAC 技术的新项目合作。2025年上半年，公司自主设计并搭建的自动化高通量化 学合成平台高效运转，由此带来 ChemSer 板块收入同比增长 94.17%。 8月27日晚间，成都先导(688222.SH)发布2025年半年度报告。2025年上半年，公司实现营业收入2.27亿 元，同比增长16.58%；实现归母净利润5004.20万元，同比增长390.72%；扣非归母净利润5391.19万 元，同比增长2517.66%；经营活动产生的现金流量净额1.11亿元，同比增长51.48%；主营业务整体毛利 率 ...

8月27日晚间，成都先导(688222)正式发布2025年半年报，报告期内，该上市公司实现营业收入2.27亿 元，同比增长16.58%；实现净利润5004.20万元，同比增长390.72%；扣非后净利润5391.19万元，同比 增长2517.66%；经营活动产生的现金流量净额1.11亿元，同比增长51.48%；主营业务整体毛利率为 53.82%，同比增长7.23个百分点。 OBT板块(基于寡核苷酸的药物研发平台)在持续拓展传统核苷单体合成业务的同时，借助递送分子相关 服务，实现了小核酸一站式项目的商业转化；TPD板块在2025年积极探索新业务模式，与合作伙伴共同 启动基于PROTAC技术的新项目合作。报告期内，成都先导自主设计并搭建的自动化高通量化学合成平 台高效运转，带动了ChemSer(基于小分子化学合成、平行合成等相关服务)收入同比增长94.17%。 资料显示，成都先导聚焦小分子及核酸新药的发现与优化，依托DEL技术(包括DEL库的设计、合成和 筛选及拓展应用)、基于分子片段和三维结构信息的药物设计(FBDD/SBDD)技术、基于寡核苷酸的药物 研发平台(OBT)、靶向蛋白降解平台相关技术(TPD)四大 ...

每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ 每经AI快讯，成都先导8月27日晚间发布公告称，本激励计划拟授予的激励对象共计115人，涉及的标 的股票来源为公司从二级市场回购的公司A股普通股股票或公司向激励对象定向发行的公司A股普通股 股票；拟向激励对象授予限制性股票105.22万股，约占本次激励计划草案公告时公司总股本约4.01亿股 的0.26%；限制性股票的授予价格为每股13.99元，即满足授予条件和归属条件后，激励对象可以13.99 元/股的价格购买公司从二级市场回购的公司A股普通股股票或公司向激励对象定向发行的A股普通股股 票，的有效期为自限制性股票授予之日起至激励对象获授的限制性股票全部归属或作废失效之日止，最 长不超过36个月。 （记者 曾健辉） ...

Group 1 - The core viewpoint of the articles highlights Chengdu XianDao's strong performance in the first half of 2025, with significant growth in revenue, net profit, and gross margin [1][2] - Chengdu XianDao achieved an operating income of 227 million yuan, a year-on-year increase of 16.58% [1] - The net profit attributable to shareholders reached 50.042 million yuan, reflecting a remarkable year-on-year growth of 390.72% [1] - The net profit after deducting non-recurring gains and losses was 53.912 million yuan, showing a substantial increase of 2517.66% year-on-year [1] - The net cash flow from operating activities was 111 million yuan, up by 51.48% compared to the previous year [1] - The overall gross margin for the main business was 53.82%, an increase of 7.23 percentage points year-on-year [1] Group 2 - Chengdu XianDao is actively seizing market opportunities and enhancing cooperation with a global perspective, optimizing international market strategies [1] - The company has made structural adjustments to R&D investments to maintain innovation capabilities while improving resource allocation efficiency [1] - Chengdu XianDao has established an ESG work system based on international and domestic standards and published its first bilingual sustainability report [1] - The Chairman and CEO, Li Jin, emphasized the company's commitment to innovation-driven development and creating sustainable value for shareholders, customers, and society [2]

Core Viewpoint - The company is set to implement a restricted stock incentive plan for 2025, which has been reviewed and approved by the Board's Compensation and Assessment Committee, ensuring compliance with relevant laws and regulations [1][3]. Group 1: Compliance and Eligibility - The company does not have any circumstances that prohibit the implementation of the stock incentive plan as per the relevant laws and regulations [1]. - The identified incentive recipients meet all eligibility criteria and do not fall under any disqualifying conditions set by regulatory authorities [2][3]. Group 2: Plan Details and Approval Process - The drafting and review process of the incentive plan aligns with the requirements of the Company Law, Securities Law, and other relevant regulations, ensuring that the plan does not infringe on the interests of the company or its shareholders [3]. - The plan requires approval from the shareholders' meeting before implementation [3]. Group 3: Benefits and Mechanism - The implementation of the incentive plan is expected to enhance the company's incentive mechanism, improve the distribution system that combines incentives and constraints, and effectively boost the cohesion of the core team and the company's core competitiveness [3].

证券代码：688222 证券简称：成都先导 公告编号：2025-038 成都先导药物开发股份有限公司 第二届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都先导药物开发股份有限公司（以下简称"公司"）第二届董事会第二十三 次会议于 2025 年 8 月 26 日在公司会议室以现场结合通讯表决方式召开，会议通 知已于 2025 年 8 月 16 日以书面方式送达全体董事。本次会议应出席董事 9 名， 实际出席董事 9 名，公司监事、董事会秘书和部分高级管理人员列席本次会议， 会议由董事长 JIN LI（李进）先生召集并主持。本次会议的召集和召开程序符合 有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议决议 合法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一） 审议通过《关于审议公司 2025 年半年度报告及其摘要的议案》 本议案经第二届董事会审计委员会第十九次会议审议通过后提交董事会。具 体内容详 ...

（一）最近 12 个月内被证券交易所认定为不适当人选； 成都先导药物开发股份有限公司监事会 关于 2025 年限制性股票激励计划相关事项的核查意见 成都先导药物开发股份有限公司（以下简称"公司"）监事会依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）、《科创板上市公司自律监管指南第 4 号－－股权激励信 息披露》等相关法律、法规及规范性文件和《成都先导药物开发股份有限公司 章程》（以下简称"《公司章程》"）的规定，对公司 2025 年限制性股票激励 计划（以下简称"本次激励计划"）相关事项进行了核查，发表核查意见如下： 一、公司不存在《管理办法》等法律、法规规定的禁止实施股权激励计划 的情形，包括： （一）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无 法表示意见的审计报告； （二）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或 无法表示意见的审计报告； （三）上市后最近 36 个月内出现过未按法律 ...

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The on-site meeting will take place at the company's conference room in Chengdu [1] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system during specified trading hours on the meeting day [1][3] - Specific voting procedures apply to margin trading, transfer, and other related accounts [2] Agenda Items - The meeting will review 10 proposals, including amendments to the company's articles of association and management assessment methods [3] - Related announcements were disclosed on August 28, 2025, on the Shanghai Stock Exchange website and various financial newspapers [3] Attendance Requirements - Shareholders must be registered by the close of trading on September 8, 2025, to attend the meeting [4] - Registration for attendance requires valid identification and proof of share ownership [5][6] Contact Information - The company has provided contact details for inquiries regarding the meeting [6]